325 related articles for article (PubMed ID: 24529213)
1. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.
Nuhn P; Vaghasia AM; Goyal J; Zhou XC; Carducci MA; Eisenberger MA; Antonarakis ES
BJU Int; 2014 Dec; 114(6b):E11-E17. PubMed ID: 24529213
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.
Pei XQ; He DL; Tian G; Lv W; Jiang YM; Wu DP; Fan JH; Wu KJ
Int Urol Nephrol; 2017 Apr; 49(4):629-635. PubMed ID: 28161841
[TBL] [Abstract][Full Text] [Related]
3. Baseline neutrophil-lymphocyte ratio is associated with outcomes in patients with castration-resistant prostate cancer treated with Docetaxel in South China.
Jiang ZG; Liao SG
Medicine (Baltimore); 2021 Oct; 100(39):e27361. PubMed ID: 34596147
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.
Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151
[TBL] [Abstract][Full Text] [Related]
5. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R
Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of neutrophil-to-lymphocyte ratio in castration resistant prostate cancer: Single-centre study of Nigerian men.
Bello JO; Olanipekun OO; Babata AL
Niger J Clin Pract; 2019 Apr; 22(4):511-515. PubMed ID: 30975955
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Armstrong AJ; Clarke SJ; Vardy JL; Templeton AJ; Wang SL; Paolini J; Chen I; Chow-Maneval E; Lechuga M; Smith MR; Michaelson MD
Clin Genitourin Cancer; 2014 Oct; 12(5):317-24. PubMed ID: 24806399
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy.
Yamashita S; Kohjimoto Y; Iguchi T; Koike H; Kusumoto H; Iba A; Kikkawa K; Kodama Y; Matsumura N; Hara I
BMC Urol; 2016 Mar; 16():13. PubMed ID: 27001073
[TBL] [Abstract][Full Text] [Related]
10. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL
Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
[TBL] [Abstract][Full Text] [Related]
12. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.
Yao A; Sejima T; Iwamoto H; Masago T; Morizane S; Honda M; Takenaka A
Int J Urol; 2015 Sep; 22(9):827-33. PubMed ID: 26087772
[TBL] [Abstract][Full Text] [Related]
13. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
Linton A; Pond G; Clarke S; Vardy J; Galsky M; Sonpavde G
Clin Genitourin Cancer; 2013 Dec; 11(4):423-30. PubMed ID: 23816526
[TBL] [Abstract][Full Text] [Related]
14. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel.
Sümbül AT; Sezer A; Abalı H; Köse F; Gültepe I; Mertsoylu H; Muallaoğlu S; Özyılkan Ö
Int Urol Nephrol; 2014 Aug; 46(8):1531-5. PubMed ID: 24526335
[TBL] [Abstract][Full Text] [Related]
16. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio.
Templeton AJ; Pezaro C; Omlin A; McNamara MG; Leibowitz-Amit R; Vera-Badillo FE; Attard G; de Bono JS; Tannock IF; Amir E
Cancer; 2014 Nov; 120(21):3346-52. PubMed ID: 24995769
[TBL] [Abstract][Full Text] [Related]
17. Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel.
Man YN; Chen YF
Int Urol Nephrol; 2019 Dec; 51(12):2189-2199. PubMed ID: 31456101
[TBL] [Abstract][Full Text] [Related]
18. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.
Boegemann M; Schlack K; Thomes S; Steinestel J; Rahbar K; Semjonow A; Schrader AJ; Aringer M; Krabbe LM
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208664
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.
Uemura K; Miyoshi Y; Kawahara T; Yoneyama S; Hattori Y; Teranishi J; Kondo K; Moriyama M; Takebayashi S; Yokomizo Y; Yao M; Uemura H; Noguchi K
BMC Cancer; 2016 Feb; 16():109. PubMed ID: 26883015
[TBL] [Abstract][Full Text] [Related]
20. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.
de Wit R; Wülfing C; Castellano D; Kramer G; Eymard JC; Sternberg CN; Fizazi K; Tombal B; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Bono J
ESMO Open; 2021 Oct; 6(5):100241. PubMed ID: 34450475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
